

Company Number: 622092

Newderm Clinic Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 April 2025

Newderm Clinic Limited
CONTENTS

	Page
Directors and Other Information	3
Directors' Responsibilities Statement	4
Balance Sheet	5
Reconciliation of Shareholders' Funds	6
Notes to the Financial Statements	7 - 11

Newderm Clinic Limited
DIRECTORS AND OTHER INFORMATION

Directors	Victoria O'Keeffe Volha Samafalava
Company Secretary	Volha Samafalava
Company Number	622092
Registered Office and Business Address	16 Stillorgan Park Avenue Blackrock Dublin A94AF38 Ireland
Accountants	TaxAssist Accountants Chartered Certified Accountants Unit 3 Dargle Centre Castle Street Bray Wicklow Ireland

Newderm Clinic Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 April 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

Victoria O'Keeffe
Director

26 March 2026

Volha Samafalava
Director

26 March 2026

Newderm Clinic Limited

BALANCE SHEET

as at 30 April 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	7	<u>520,305</u>	<u>533,520</u>
Current Assets			
Debtors	8	1,330	98,578
Cash and cash equivalents		<u>10,632</u>	<u>36,612</u>
		<u>11,962</u>	<u>135,190</u>
Creditors: amounts falling due within one year	9	<u>(347,588)</u>	<u>(489,455)</u>
Net Current Liabilities		<u>(335,626)</u>	<u>(354,265)</u>
Total Assets less Current Liabilities		<u>184,679</u>	<u>179,255</u>
Creditors:			
amounts falling due after more than one year	10	<u>(25,799)</u>	<u>(38,880)</u>
Net Assets		<u><u>158,880</u></u>	<u><u>140,375</u></u>
Capital and Reserves			
Called up share capital presented as equity		100	100
Retained earnings		<u>158,780</u>	<u>140,275</u>
Equity attributable to owners of the company		<u><u>158,880</u></u>	<u><u>140,375</u></u>

We as Directors of Newderm Clinic Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 26 March 2026 and signed on its behalf by:

Victoria O'Keeffe
Director

Volha Samafalava
Director

Newderm Clinic Limited
RECONCILIATION OF SHAREHOLDERS' FUNDS

as at 30 April 2025

	Called up share capital €	Retained earnings €	Total €
At 1 May 2023	100	80,697	80,797
Profit for the financial year	-	59,578	59,578
At 30 April 2024	100	140,275	140,375
Profit for the financial year	-	18,505	18,505
At 30 April 2025	100	158,780	158,880

Newderm Clinic Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

1. General Information

Newderm Clinic Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 622092. The registered office of the company is 16 Stillorgan Park Avenue, Blackrock, Dublin, A94AF38, Ireland which is also the principal place of business of the company. The activity of the company continued to be that of Hairdressing and Other Beauty Treatment. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 30 April 2025 have been prepared on the going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102).

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014.

Cash flow statement

The company has availed of the exemption in FRS 102 from the requirement to prepare a Cash Flow Statement because it is classified as a small company.

Turnover

Turnover comprises the invoice value of services supplied by the company, exclusive of trade discounts and value added tax.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	-	Nil
Fixtures, fittings and equipment	-	12.50% Straight line
Motor vehicles	-	12.50% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Leasing and hire purchases

Tangible assets held under leasing and Hire Purchases arrangements which transfer substantially all the risks and rewards of ownership to the company are capitalised and included in the Balance Sheet at their cost or valuation, less depreciation. The corresponding commitments are recorded as liabilities. Payments in respect of these obligations are treated as consisting of capital and interest elements, with interest charged to the Profit and Loss Account.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Newderm Clinic Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating profit	2025	2024
	€	€
Operating profit is stated after charging:		
Depreciation of tangible assets	<u>13,930</u>	<u>13,840</u>
4. Interest payable and similar expenses	2025	2024
	€	€
Interest	<u>1,996</u>	<u>4,254</u>

5. Employees

The average monthly number of employees, including directors, during the financial year was 1, (2024 - 2).

	2025	2024
	Number	Number
Director	-	1
Employee	<u>1</u>	<u>1</u>
	<u>1</u>	<u>2</u>

Newderm Clinic Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

6. Tax on profit

	2025 €	2024 €
(a) Analysis of charge in the financial year		
Current tax:		
Corporation tax at 12.50% (2024 - 12.50%)	9,000	11,880
Under/over provision in prior financial year	2,888	2,584
Total current tax	<u>11,888</u>	<u>14,464</u>

(b) Factors affecting tax charge for the financial year

The tax assessed for the financial year differs from the standard rate of corporation tax in the Republic of Ireland 12.50% (2024 - 12.50%). The differences are explained below:

	2025 €	2024 €
(Loss)/profit taxable at 12.50%	(5,607)	53,042
Profit taxable at 25%	36,000	21,000
Profit before tax	<u>30,393</u>	<u>74,042</u>
Profit before tax multiplied by the standard rate of corporation tax in the Republic of Ireland at 12.50% (2024 - 12.50%)	(701)	6,630
Profit before tax multiplied by 25%	9,000	5,250
	<u>8,299</u>	<u>11,880</u>
Effects of:		
Tax loss carried forward	701	-
Adjustment to tax charge in respect of previous periods	2,888	2,584
Total tax charge for the financial year (Note 6 (a))	<u>11,888</u>	<u>14,464</u>

7. Tangible assets

	Land and buildings freehold €	Fixtures, fittings and equipment €	Motor vehicles €	Total €
Cost				
At 1 May 2024	460,361	70,731	39,995	571,087
Additions	-	715	-	715
At 30 April 2025	<u>460,361</u>	<u>71,446</u>	<u>39,995</u>	<u>571,802</u>
Depreciation				
At 1 May 2024	-	27,568	9,999	37,567
Charge for the financial year	-	8,931	4,999	13,930
At 30 April 2025	<u>-</u>	<u>36,499</u>	<u>14,998</u>	<u>51,497</u>
Net book value				
At 30 April 2025	<u>460,361</u>	<u>34,947</u>	<u>24,997</u>	<u>520,305</u>
At 30 April 2024	<u>460,361</u>	<u>43,163</u>	<u>29,996</u>	<u>533,520</u>

Newderm Clinic Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

8. Debtors	2025	2024
	€	€
Trade debtors	<u>1,330</u>	<u>98,578</u>
9. Creditors	2025	2024
Amounts falling due within one year	€	€
Amounts owed to credit institutions	12,072	-
Net obligations under finance leases and hire purchase contracts	8,159	-
Trade creditors	21,039	26,540
Taxation	56,556	71,846
Directors' current accounts (Note 13)	238,495	376,227
Other creditors	11,267	11,242
Accruals	-	3,600
	<u>347,588</u>	<u>489,455</u>
10. Creditors	2025	2024
Amounts falling due after more than one year	€	€
Bank loan	8,868	6,520
Finance leases and hire purchase contracts	16,931	32,360
	<u>25,799</u>	<u>38,880</u>
Loans		
Repayable in one year or less, or on demand	12,072	-
Repayable between one and two years	-	6,520
Repayable between two and five years	8,868	-
	<u>20,940</u>	<u>6,520</u>
Net obligations under finance leases and hire purchase contracts		
Repayable within one year	8,159	-
Repayable between one and five years	16,931	32,360
	<u>25,090</u>	<u>32,360</u>
11. Income Statement	2025	2024
	€	€
At 1 May 2024	140,275	80,697
Profit for the financial year	18,505	59,578
At 30 April 2025	<u>158,780</u>	<u>140,275</u>
12. Capital commitments		
The company had no material capital commitments at the financial year-ended 30 April 2025.		

Newderm Clinic Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

13. Directors' remuneration and transactions	2025	2024
	€	€
Remuneration	-	6,428
	<u> </u>	<u> </u>

The following amounts are repayable to the directors:

	2025	2024
	€	€
Victoria O'Keeffe	238,495	376,227
	<u> </u>	<u> </u>

14. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

15. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 26 March 2026.